NCT07634978Recruiting
Development and Application of an AI Chatbot for Perioperative Health Education in Thyroid Cancer Patients
Development and Application of an Artificial Intelligence Chatbot for Perioperative Health Education Among Thyroid Cancer Patients: A Quasi-Experimental Study
Source: ClinicalTrials.gov · Last updated 9 Jun 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the usefulness and effectiveness of a newly developed artificial intelligence (AI) chatbot for health education in thyroid cancer patients during the period around their surgery (the perioperative period). The main questions it aims to answer are: Does the AI chatbot improve patients' readiness for discharge, quality of recovery, and active engagement in their own healthcare compared to traditional education methods? How do patients rate the usability and friendliness of this new AI chatbot system? Researchers will compare a group of patients who receive traditional health education (the control group) with a subsequent group of patients who use the new AI chatbot built on the "Coze" platform (the intervention group) to see if the AI chatbot leads to better recovery experiences and higher patient engagement. Participants will be asked to: Access and interact with the AI chatbot to receive personalized health guidance, ask questions, and get instant feedback during their hospital stay. Complete a set of questionnaires on the morning of their hospital discharge to evaluate their recovery quality, readiness to leave the hospital, and level of engagement in their care. Complete an extra survey regarding the usability and acceptability of the chatbot system (only for participants in the AI chatbot group).
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 3 Jun 2026
- Start date
- 1 Jan 2026
- Primary completion date
- 1 Aug 2026
- Lead sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Diseases
- Thyroid cancer
- NCT number
- NCT07634978
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 1 Jan 2026 to the primary completion date, 1 Aug 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Concurrently diagnosed with malignant tumors in other organs or severe complications/dysfunctions of other major organs.
Age
- Aged less than 18 years.
Other
- Patients who are anticipated to be unable to complete the study protocol due to plans for hospital/department transfer, or high risk of treatment discontinuation.
Who the study is looking for
- Diagnosed with thyroid cancer in accordance with the clinical diagnostic criteria, and confirmed by ultrasonography and histopathological examination.
- Scheduled to undergo elective surgery for thyroid cancer.
- Mentally competent to understand the study protocol, and voluntarily provided written informed consent to participate in this study.
Age in the registry: 18 years to 60 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.